Friday, 17 August 2018

Global Cosmetic Surgery Market 2018 Size, Status and Forecast to 2023

Market Scenario:
Plastic surgery is a special segment of surgery field which is involved in the restoration, reconstruction, or alteration of the human body so as to enhance the body’s appearance. The market for cosmetic surgery is driven by
Social and cultural factors such as influence of media, fashion and film industry, peer pressure for appearance and beauty, changing dimensions of beauty etc. The growth of the tourism industry and formation of tourism clusters such as Miami, Bangkok etc. has not only increased exposure to cosmetic surgeries but have also created a high point demand for these surgeries. The American society for aesthetic plastic surgery estimates that, for the year 2013, there was a 6.5% increase in the total number of cosmetic surgical procedures over 2012, with almost 1.9 million surgical procedures performed in 2013. Thus there has been rising trend of cosmetic surgeries with a hefty 40% growth with men
Health factors such as rise in obesity, accidents, the growing safety margin of cosmetic surgery, growing number of cosmetic surgery hospitals etc.
Technological factors such as development of advanced materials such as silicone implants etc.
Economic factors such as growing per capita income, falling cost of cosmetic surgeries etc.
Moreover factors restraining the market are non-essential nature of cosmetic surgery, social taboos against violation of body parts, high cost of cosmetic surgeries despite reduction etc. 
Considering all these factors the market for cosmetic surgery is expected to reach $ 21.97 billion by the end of 2023, this market is projected to growing at a CAGR of ~7.8% during 2017-2023.
Key players of Global Cosmetic Surgery Market:
Key players profiled in the report are Johnson & Johnson, Valeant Pharmaceuticals International, Cutera, Inc., Syneron Medical Ltd., Allergan, Inc., Genesis Biosystems, Inc. and others.
Segments:
The Global cosmetic surgery market is segmented on the basis of surgery type. Based on the surgery type, the market has been segmented as liposuction, eyelid and nose surgery, body contouring, facial reconstruction, cosmetic implants and others. The body contouring segment is further sub segmented into tummy tuck, breast lift, others. Similarly the cosmetic implants segment is sub segmented into breast augmentation, buttock implants, chin & cheek implants.

Regional analysis
US accounts for the maximum market share of the global cosmetic surgery market and the market is expected to increase continuously in coming years. This can be attributed to increasing pool of awareness and the growing acceptability of cosmetic surgery. Advancing technologies within the cosmetic surgery such as advanced silicone and polymer implants is also driving the market. However there is a definite shift of cosmetic surgery market to Asia pacific and Latin America with the most active part played by tourism industry.
Detailed Table of Contents:
1 Introduction
1.1 Definition
1.2 Scope Of Study
1.2.1 Research Objective
1.2.2 Assumptions & Limitations
1.2.2.1 Assumptions
1.2.2.2 Limitations
1.3 Market Structure:
2 Research Methodology
2.1 Research Process:
2.2 Primary Research
2.3 Secondary Research:
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Macroeconomic Indicators
4 Market Factor Analysis
4.1 Porters Five Forces Model
4.2 Bargaining Power Of Suppliers
4.3 Bargaining Power Of Buyers
4.4 Threat Of New Entrants
4.5 Threat Of Substitutes
4.6 Intensity Of Rivalry
...Continued
         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels: , , ,

Thursday, 16 August 2018

Influenza Diagnostics Market 2018 Global Analysis, Growth, Size, Share, Trends, Forecast to 2023

Global Influenza Diagnostics Market is growing moderately. Influenza or flu is one of the common medical condition which occur in seasonal epidemics and shows an acute illness with variable degrees of systemic symptoms which ranges from mild fatigue to respiratory failure and death. Influenza B is most common type of flu. Influenza infection can create health complications which may be deadly, but early diagnosis of influenza can reduces the chances of further complications. According the World Health organization, there are almost 600 million cases of influenza worldwide. The increasing demand for advanced diagnostic products and kits, increasing R&D funding for new innovative products and increasing healthcare expenditure are major driving factors for this market. The Global Influenza Diagnostics market is expected to reach US$ 700.7 million by 2023 and is projected to grow at the CAGR of ~5.8% during the forecast period from 2017-2023.
Market Research Future (MRFR) has published a report about the global influenza diagnostics market. This report expects 5.8% CAGR during the forecast period between 2017 and 2023. In terms of cash, this market is expected to grow with US $ 700.7 mn by 2023. This report analyzes the market, potential for growth during the forecast period, market sizes around the world, key players in the market, product launches and latest research and development (R&D). The global influenza diagnostics market is on the basis of types, tests, and region. The segmentation of types comprises of type A flu, type B flu, type C flu. The three forms of type A are bird flu, seasonal flu, and Swine flu. On the basis of direct fluorescent antibody (DFA) tests, molecular tests, nucleic acid sequence-based amplification (NASBA) tests, rapid influenza detection tests (RIDT), serological assays, simple amplification-based assays (SAMBA) and loop-mediated isothermal amplification-based assays (LAMP). Serological assays are segmented into primary serological tests, secondary serological tests, and tertiary serological tests. Primary serological tests cover enzyme-linked immunosorbent assay (ELISA), immunofluorescent antibody technique (IFAT) and radioimmunoassay (RIA). Secondary Serological tests include agglutination tests, complement fixation tests (CFT), precipitation tests, serum neutralization tests (SNT) and toxin-antitoxin test.
Key Players for Global Influenza Diagnostics Market:                               
Some of the key players in this market are: Alere (US), BD (US), Becton, Dickinson and Company (U.S.), Cepheid (US), bioMérieux SA (France), Hardy Diagnostics(us), LifeSign LLC.(US), Meridian Bioscience, Inc.(US), Quidel Corporation (US), Roche Molecular Systems Inc.(Switzerland), Sekisui Diagnostics (US)
Segments:                                                                                                                                        
Global Influenza Diagnostics Market has been segmented on the basis of type of flu which comprise Type A flu (Seasonal flu, Swine Flu, Bird Flu), type B flu, Type C flu. On the basis of type of test it segmented into Molecular Tests, Rapid Influenza Detection Tests (RIDT), Direct Fluorescent Antibody (DFA) Tests, Nucleic Acid Sequence-based Amplification (NASBA) Tests, Serological Assays, Simple Amplification-based Assays (SAMBA), Loop-mediated Isothermal Amplification-based Assays (LAMP), and Others. Serological assays further sub segmented into Primary Serological tests (Enzyme linked immunosorbent assay (ELISA), Immuno fluorescent antibody technique (IFAT), Radio immuno assay (RIA), Secondary Serological tests (Agglutination tests, Complement fixation tests (CFT), Precipitation tests, Serum neutralization tests (SNT), Toxin-antitoxin test), and Tertiary serological tests.
Regional Analysis of Global Influenza Diagnostics Market:                  
Considering the global scenario of the market, North America is believed to be the largest market for Global Influenza Diagnostics due to advanced healthcare facilities and increasing presence of major players in this region. Moreover, the European market second largest market for Global Influenza Diagnostics. In Europe, Western Europe accounts the largest market share. While Asia-Pacific is expected to grow at significant rate in the Global Influenza Diagnostics market during the forecasted period. Middle East and Africa is likely to have a limited growth in the market due to less awareness of these therapies and treatment.  
Detailed Table of Contents:
1 Report Prologue 
2 Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
2.3 Market Structure
2.4. Market Segmentation
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Mega Trends
4.5 Macroeconomic Indicators
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Porters Five Forces
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
5.5 Investment Opportunity Analysis
...Continued


         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels: ,

Protein Assays Market Global Research Report 2018 Analysis & Forecast to 2023

Market Scenario
The Global Protein Assay Market is expected to witness considerable growth during the forecast period, mainly due to the increasing investment by pharma and biotech companies in research and development (R&D) and funding by governments of various countries for proteomics research.
Protein quantification is pivotal part of daily workflow of protein extraction in biochemistry and molecular biology labs that involves protein extraction, analysis or labeling. Favorable government policies for proteomics research, and the presence of a large number of players in the global protein assay market are the key factors driving the growth of the market during the forecast period.
Several new biomarker identification systems are launched by the key players which grants various opportunities for the global protein assay market. For instance, in June 2017, Gyros Protein Technologies AB launched a new version of its anti-drug antibody (ADA) solution for the immunogenicity market. This solution enables customers to automatically run the assays in a time-efficient manner using small volumes of patient samples and reagents, and shorten run-times.
According to a publication by Pharmaceuticals Research and Manufacturers of America (PhRMA), the organizations spent approximately $58.8 billion on R&D in 2015 accounted for the largest part of all the biopharmaceutical R&D spending in the U.S. However, high cost of multiplex assay hardware is limiting the growth of global protein assay market.
The global market of protein assays is expected to grow at a CAGR of approximately 10.8% during the forecast period 2017-2023.
Segmentation
The protein assays is segmented on the basis of type, application, product, technology and end-users.
On the basis of type, the market is segmented into copper-ion-based assays, test strip-based assays, dye-binding assays, and others 
On the basis of application, market is segmented into diagnosis, drug discovery, protein purification and others
On the basis of product market is segmented into reagents & kits, instruments and others
On the basis of technology, market is segmented into colorimetric-based protein assays, fluorescence-based protein assays, and absorbance-based protein assays
On the basis of end-user, the market is segmented into hospitals & diagnostic centers, academic institutes, pharmaceutical & biotechnology companies and others.
Regional Analysis
The global protein assays market consists of countries namely America, Europe, Asia Pacific, and the Middle East.
North America is projected to hold the largest share of the global protein assay market due to presence of superior research and development base, strong regional economics, and greater emphasis on disease prevention and wellness by governments.
The European protein assay market is expected to witness rapid growth owing to the high investment in various private and government funded research and development programs in the region and increased spending on pharmaceutical and biotechnology industry development.
Countries such as China, Japan, and India in Asia Pacific are also poised to be promising markets for protein assay in the near future. The healthcare expenditure in Asia increased due to an extension of state health care programs and the increasing affluence of the population. India is anticipated to witness an expansion in spending due to a government resolution to enhance healthcare services. Moreover, China and South Korea are striving to develop their biotechnology sector for diagnosis purpose. China’s efforts to develop its biotech sector has shown good results in sectors such as vaccines and biological products and the same can be expected in the protein assays industry. However, low research and development (R&D) yields, high infrastructure cost, stringent regulatory framework, and lack of trained resources are some of the restraints of the protein assay market.
The Middle East region is expected to grow at a faster rate due to the factors such as the extensive development of health care infrastructure and growing emphasis on research and development in the health care sector.
Key Players
Many new companies have jumped into the market in order to make the most out of the opportunities. Companies are implementing the strategies of mergers and acquisitions with other players. For instance, in June 2015, Thermo Fisher Scientific Inc. introduced the Orbitrap Fusion Lumos Tribrid mass spectrometer and updated the device in 2017.
Some of key the players in the global protein assays market are GE Healthcare (U.S.), Thermo Fisher Scientific (U.S.), Bio-Rad Laboratories Inc. (U.S.), Merck KGaA (Germany), Cell Signaling Technology Inc. (U.S.), Abcam plc (U.S.), Lucigen Corporation (U.S.), PerkinElmer Inc. (U.S.), QIAGEN (Germany), Lonza Group Ltd. (Switerzland), Bio-Techne (U.S.), BioVision Inc. (U.S.), Illumina Inc. (U.S.), New England Biolabs (U.S.), Takara Bio Inc. (Japan), Promega Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switerzland), and others.
Detailed Table of Contents:
1 Report Prologue
2 Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
2.3 Market Structure
2.4. Market Segmentation
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Mega Trends
4.5 Macroeconomic Indicators
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Porters Five Forces
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
5.5 Investment Opportunity Analysis
...Continued
         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Saturday, 11 August 2018

Antipsychotic Drugs Market 2018 - Opportunity, Driving Trends and deep study 2023

Market Scenario: 
Psychosis are a group of disorders with serious distortion of thought, behavior, recognition of reality and perception. The patient may have delusions and hallucinations and may have misperception and wrong evaluation of situation, facts or other people.
The most critical market driving factor for anti-psychotic drugs is the rising cases of psychosis and mental disorders. Following are some estimates about psychosis according to the World Health Organization (WHO):
Depression affects an estimated 300 million people in the world.
Bipolar affective disorder takes a toll on about 60 million people worldwide.
Schizophrenia, a severe mental disorder, affects about 21 million people worldwide.
Dementia has a prevalence in about 47.5 million people worldwide
One fourth of people are affected by mental or neurological disorders at some point in their lives.
The current number of untapped patients are of an order of around 450 million currently suffering from such conditions. 
The treatment scenario is no different and the least it is said the better. According to WHO, the gap between the unmet needs in low- and middle-income countries is between 76% and 85% of people with mental disorders. Even in high-income countries the unmet medical needs gap is of an order of 35% and 50% of people with mental disorders. Thus there exists a huge market with unmet medical needs which needs to be tapped. Other very important market driving factor is increasing focus of governments and health care organizations on mental health. For example, WHO's initiated its Mental Health Gap Action Programme in 2008, to expand the coverage of mental health treatment and service across the world.
However there are huge formidable barriers which remain a challenge to expand the market and the anti-psychotic drugs market has shown growth par below their potential market due to a host of factors. The critical market restraint is the poor efficiency and efficacy of anti-psychotic drugs. The side effects of these drugs is another depressing story to tell, which ranges from insomnia, drowsiness, vomiting to the high addiction rate. Social stigma also constraints the market with an estimated two-thirds of patients never seeking help. The poor drug development pipeline is a future market threat. The drug pipeline for anti-psychotics is devoid of any novel acting drug candidate. Strict regulatory framework is another deterrent for companies developing anti-psychotics.
The global market for antipsychotic drugs is expected to reach around USD 18.5 billion by the end of the forecast period and is expected to grow at a CAGR of ~4.3%.
Key Players for Global Antipsychotic Drugs Market:
Some of the key players in this market are: Eli Lilly & Co., Bristol-Myers Squibb, AstraZeneca, Pfizer inc., GlaxoSmithKline plc., Johnson & Johnson  and others.
Segments:
Global antipsychotic drugs market has been segmented on the basis of therapeutic applications, which comprises schizophrenia, bipolar disorder, depression, dementia and others. On the basis of generations; market is segmented into first, second and third.
Regional Analysis of Global Antipsychotic Drugs Market:
Globally America is the largest market for antipsychotic Drugs. The American market for antipsychotic drugs represents about 47 % of world market in 2016. Rapid uptake of new drug molecules and excellent reimbursements scenario in the U.S. are the two most important factors for the dominance of America. Europe is the second-largest market for antipsychotic drugs. Asia pacific region is expected to be fastest growing region in antipsychotic drugs market.
Detailed Table of Contents:
1 Introduction
1.1 Definition
1.2 Scope Of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure:
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
3.5 Macroeconomic Indicators
...Continued
         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Friday, 10 August 2018

Performance Enhancing Drugs Market to show steady growth, 2018

Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Performance Enhancing Drugs Market Research Report – Global Forecast till 2023” Gives industry size, top players and worldwide demand
Market Scenario
Performance enhancing drugs are chemical agents designed to provide an advantage in athletic performance. Muscle enlargement, increased blood’s oxygen carrying capacity are some of the effects induced by the consumption of the performance enhancing drugs. In 2015, according to Health Research Funding ~1,084,000 Americans were reported to use anabolic performance enhancing drugs. Along with such trends in the usage of the performance enhancing drugs, increasing acceptance is facilitating the market growth. Approximately 57% of the steroid users said that they would continue to use steroids even if it shortens there life. Moreover, increasing use of the anabolic steroids for the treatment of medical conditions such as anaemia, certain kinds of breast cancer besides others is expected to fuel the market growth during the forecasted period. However, the use of such drugs leads to various side effects. Some of the side effects observed in males are acne, diminished sperm production; in females,  masculinization, heart attack, etc. Moreover, in 2014 according to the Health Research Funding, the percentage of positive tests for anabolic drugs doping in world was about 50.6%. Such cases of doping made the governments to formulate strict guidelines for the usage and sales of performance enhancing drugs. This is expected to restrict the market growth during the forecasted period.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4695     
The global market for performance enhancing drugs is expected to grow at an approximate CAGR of 4.8%. 
Segmentation
The global performance enhancing drugs market is segmented on the basis of types, products, and end users.
On the basis of types, the market is segmented into ergogenic aids, nootropic, and others. The ergogenic aids segment by types is sub-segmented into anabolic steroids, dehydroepiandrosterone (DHEA), human growth hormone, and others. The nootropic segment by types is further segmented into racetams, ampakines, choline & acetylcholine intermediates, others.
On the basis of the products, the market is categorised into pills, injections, patches, and others
On the basis of end users, the market is segmented into athletes, body builders, students, militaries, and others.
Regional Analysis
The Americas dominates the global performance enhancing drugs market owing to the presence of well-developed economies with high per capita income within the region like the U.S. and Canada. In 2017, according to the American Cancer Society in the U.S., about 252,710 new cases of invasive breast cancer diagnosed in women. Moreover, it is predicted that by the end of 2017, 40,610 women would die from breast cancer. This will boost the market growth during the forecasted period as anabolic steroids can be for the treatment of certain types of breast cancer.
Europe is the second largest performance enhancing drug market, which is followed by Asia Pacific. Availability of funds for research and increasing acceptance of the performance enhancing drugs within the region likely to boost the market.
Asia Pacific is the fastest growing region for the market due to the increasing awareness of the performance enhancing drugs, continuously developing economies, and presence of huge opportunity in the market.
On the other hand, the Middle East & Africa owns the least share of the global performance enhancing drugs market due to presence of poor economy, especially, in Africa region. Majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure.
Key players for global performance enhancing drugs market
The key players in the global performance enhancing drugs market are Taj Pharmaceuticals Limited. (India), Balkan Pharmaceuticals. (Europe), Bayer AG (Europe), AstraZeneca (Europe), Novo Nordisk A/S (Europe), BrainAlert, LLC (U.S.), Douglas Laboratories. (U.S.), Onnit Labs, LLC. (U.S.), Eli Lilly and Company. (U.S.), and others.
Apply for Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/4695
Detailed Table of Contents:
1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3 Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
...Continued
Send An Enquiry @ https://www.marketresearchfuture.com/enquiry/4695
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Pericardium Diseases Market in depth study and analysis published, 2018

Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Pericardium Diseases Market Research Report – Global Forecast till 2023” Gives industry size, top players and worldwide demand
Market Scenario:
The pericardium is a double-layered, tough, collagenous membrane, which surrounds the heart. They play an important role in the protection of the health from external shock. Nowadays, a number of companies manufacture artificial tissue membrane, which is widely used in the surgical procedures of pelvic floor reconstruction and bariatric stomach reduction. Many factors are responsible for the diseases, which includes infections, heart surgery, trauma, cancer and many other diseases. Pericarditis is the most common type of the disease. It affects people of all ages, however, men between 20 years-50 years are more likely to develop the disease. In 15%-30% cases, it develops into chronic pericarditis. Increasing prevalence of pericarditis across the globe is a major driver of the market. According to the Health Grades Inc, 1 in every 2,000 individual have pericarditis. Additionally, high healthcare expenditure, increasing demand for the better treatment, and rising number of patients with heart diseases are providing support for the growth of the market. However, available treatments are costly and are not affordable to peoples in developing countries. Thus, the high cost of the treatment may slow the growth of the market.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4897
The global pericardium diseases market is expected to grow at a CAGR of ~8.2 % during the forecast period 2017-2023. 
SegmentationThe global pericardium diseases market is segmented on the basis of types, treatment, and end users.
On the basis of the types, the market is segmented into acute pericarditis, hemopericardium, pericarditis, tuberculous pericarditis, and others.
On the basis of the treatment, the market is segmented into diagnostic test, and disease treatment. The diagnostic treatment is further segmented into the physical exam, EKG, chest X-ray, echocardiography, cardiac CT, cardiac MRI, and others. The diseases treatment is sub-segmented into anti-inflammatory drugs, pericardium patches, surgery, and others.
On the basis of the end users, the market is segmented into hospital & clinics, ambulatory centers, and others.
Regional AnalysisThe Americas account for the major share of the global pericardium diseases market owing to the increasing number of patients with pericardium diseases, well-developed technology, and increasing government support for research & development. Additionally, high healthcare expenditure and changing lifestyle have fuelled the growth of the Americas pericardium diseases market. Presence of major players in this region is likely to support the growth of the market during the forecasted period.
Apply for Exclusive Discount @ https://www.marketresearchfuture.com/sample_request/4897
Europe holds the second largest pericardium diseases market, which is followed by Asia Pacific. Strong government support and availability of the funds for research & development have driven the market growth. Germany and the U.K are the major contributors to the market. Asia Pacific is the fastest growing pericardium diseases market owing to the presence rapidly developing the economy, increasing the prevalence of cancer and other heart diseases, and increasing government support.
On the other hand, the Middle East & Africa hold the least share of the market due to poor political conditions in Africa, and limited availability of funds and medical facilities. The Middle East dominates the Middle East & Africa pericardium disease market due to the presence of well-developed countries like Kuwait, Qatar, Oman, and South Arabia. However, due to the presence of a huge opportunity for the development of the market, Africa region is expecting a healthy growth.
Intended Audience
  • Pharmaceutical Companies
  • Government and private research companies
  • Research and Development (R&D) Companies
  • Drug Manufacturers and Suppliers
  • Medical Research Laboratories 
Key Players in Global Pericardium Market
Some of key the players in the market are Smith and Nephew (U.K), Teva Pharmaceutical (Isreal), GlaxoSmithKline Plc. (U.K), Novartis AG (Switzerland), Eli Lilly and Company (U.S.), Arthrex, Inc.(U.S.), Medtronic (U.K), Edwards Lifesciences (U.S.), Abbott Laboratories (U.S.), Johnson & Johnson Services, Inc. (U.S.), C.R. Bard Inc (U.S.)Allergan (U.S.), Integra Lifesciences (U.S.), Livanova(U.K), and Zimmer Biomet (U.S.)
Table Of Content
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Send An Enquiry @ https://www.marketresearchfuture.com/enquiry/4897
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Antihelminthics Market Shares Analysis, Key Development Strategies and Forecasts Till 2023

Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Antihelminthics Market Research Report- Global Forecast till 2023” Gives industry size, top players and worldwide demand
Market Synopsis of Global Antihelminthics Market
Market scenario
Antihelminthics are a group of antiparasitic drugs that kill and expel parasitic worms & other internal parasites from the body without causing any significant damage to the patient. These drugs are used for the treatment of various diseases such as fasciolasis, filariasis, angiostrongylosis, and many others. Increasing prevalence of diseases such as schistosomiasis, whipworm infection, ascariasis, and other intestinal infections have boosted the growth of the antihelminthic drugs market. According to the World Health Organization (WHO) in 2014, over 1.5 billion people were infected with soil-transmitted helminthes worldwide. Additionally, a latest report published by the WHO says that more than 880 million children are in the need of treatment for these parasitic diseases. A number of different types of antiparasitic drugs are available in the market for the treatment of the different parasitic diseases. According to a research, ascariasis remains the most common intestinal parasite with 807–1221 million infections globally. It is the most prevalent diseases in East Asia, sub-Saharan Africa, and India. Majority of the patients are in developing region due to unhygienic condition. Over 65% of the patient population suffering from parasitic diseases are present in East Asia, sub-Saharan Africa, and India. Moreover, increasing geriatric population, rapidly developing healthcare sector, and increasing demand for the treatment of the parasitic diseases have fuelled the market growth. On the other hand, the side effects associated with the treatment may slow the market growth over the review period.
The global antihelminthics market is expected to grow at a CAGR of ~5.3 % during the forecast period 2017-2023.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4500
Segmentations
The global antihelminthics market is segmented on the basis of types, application, and end user.
On the basis of types, the market is segmented into benzimidazoles, abamectin, salicylanilides, praziquantel and others. Benzimidazoles is further segmented into albendazole, mebendazole, benzimidazoles, thiabendazole, and others. Salicylanilides is further segmented into niclosamide, oxyclozanide, rafoxanide, and others.
On the basis of applications, the market is segmented into schistosomiasis, fasciolasis, filariasis, angiostrongylosis, ascariasis, giardiasis and others.
On the basis of end user, the market is segmented into hospitals, clinics, and others.
On the basis types, benzimidazoles holds the major share in the market due to their long history and efficiency. A number of different types of benzimidazoles are available in the market, however, certain side effects are observed in the patient, which may slow the growth of the benzimidazoles market.
Regional Analysis
The Americas dominate the global antihelminthics market owing to the increasing prevalence of people with parasitic diseases and presence of huge geriatric population. Additionally, well-developed technology, huge number of patients suffering from autoimmune diseases, and strong government support for research & development will fuel the market growth.
Europe is the second leading market across the globe, which is followed by Asia Pacific. Huge geriatric population, availability of funds for research, and government support for research & development will drive the market.
Asia Pacific is the fastest growing antihelminthics market due to the presence of huge patient pool, rapidly growing economy, increasing prevalence of digestive diseases, and presence of huge geriatric population. Some of the regions in the Asia Pacific is still lack the proper hygiene which has led to the growth of the market in this region.
On the other hand, the Middle East & Africa holds the least share of the market owing to limited availability of medical facilities, less availability of funds, and poor political conditions in Africa. Majority of the market of this region is held by Middle East due to a well-developed healthcare sector and huge healthcare expenditure.
Key Players
Some of key the players in the market are Abbott (US), Novartis AG (Switzerland), ZEISS International (Germany), Johnson & Johnson Services, Inc. (US), Sanofi (US), Merck & Co., Inc. (US), GlaxoSmithKline plc. (US), Astellas Pharma Inc. (Japan), Bayer AG (Germany), Mentis Pharma Ltd. (India), Pfizer Inc. (US), Sanofi (France), ALLERGAN (Ireland), and AstraZeneca (UK)
Apply for Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/4500    
Detailed Table of Contents:
1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3 Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4 Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
10 Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View Point
12.1.2 Unmet Needs Of The Market
12.2 Key Companies To Watch
12.3 Prediction Of Ophthalmic Industry
13 Appendix
...Continued!
 Send An Enquiry @ https://www.marketresearchfuture.com/enquiry/4500  

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Subscribe to: Comments (Atom)